[go: up one dir, main page]

CA2249390A1 - Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor - Google Patents

Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor

Info

Publication number
CA2249390A1
CA2249390A1 CA002249390A CA2249390A CA2249390A1 CA 2249390 A1 CA2249390 A1 CA 2249390A1 CA 002249390 A CA002249390 A CA 002249390A CA 2249390 A CA2249390 A CA 2249390A CA 2249390 A1 CA2249390 A1 CA 2249390A1
Authority
CA
Canada
Prior art keywords
melanoma
specific
cytotoxic lymphocytes
uses therefor
restricted cytotoxic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002249390A
Other languages
French (fr)
Other versions
CA2249390C (en
Inventor
Craig L. Slingluff
Donald F. Hunt
Jeffrey Shabanowitz
Andrea L. Cox
Victor H. Engelhard
David Kittlesen
Jonathan Skipper
Ronald C. Hendrikson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2249390A1 publication Critical patent/CA2249390A1/en
Application granted granted Critical
Publication of CA2249390C publication Critical patent/CA2249390C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Melanoma-specific, A1-restricted CTL epitopes have been identified in tyrosinase, and may be used in conjunction with other A1- A2- and/or A3-restricted epitopes of tyrosinase, pMel-17 and other melanoma antigens in the design of vaccines.
CA002249390A 1996-03-19 1997-03-17 Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor Expired - Fee Related CA2249390C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1397296P 1996-03-19 1996-03-19
US60/013,972 1996-03-19
US2762796P 1996-10-04 1996-10-04
US60/027,627 1996-10-04
PCT/US1997/004958 WO1997034613A1 (en) 1996-03-19 1997-03-17 Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor

Publications (2)

Publication Number Publication Date
CA2249390A1 true CA2249390A1 (en) 1997-09-25
CA2249390C CA2249390C (en) 2007-12-18

Family

ID=26685490

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002249390A Expired - Fee Related CA2249390C (en) 1996-03-19 1997-03-17 Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor

Country Status (4)

Country Link
EP (1) EP0921805A4 (en)
AU (1) AU712820B2 (en)
CA (1) CA2249390C (en)
WO (1) WO1997034613A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2763071B1 (en) * 1997-05-07 2003-05-16 Centre Nat Rech Scient PEPTIDE ANALOGS AND THEIR USES IN PARTICULAR IN PHARMACEUTICAL COMPOSITIONS AND FOR DIAGNOSIS
AU2016199A (en) * 1998-12-24 2000-07-31 New York Medical College Peptide mimics useful for treating disease
WO2000047229A2 (en) * 1999-02-11 2000-08-17 Genzyme Corporation Polynucleotide encoding multimers of antigenic peptides in order to enhance presentation of the antigenic peptide by mhc molecules
WO2001030847A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
WO2001032193A1 (en) * 1999-10-29 2001-05-10 Argonex Pharmaceuticals Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma
US6861234B1 (en) * 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
WO2001092307A2 (en) * 2000-05-31 2001-12-06 Genzyme Corporation Therapeutic compounds for ovarian cancer
WO2002060390A2 (en) * 2001-01-04 2002-08-08 Yale University Induction of immune responses to isoaspartyl-modified antigens
CN101024842A (en) 2001-11-07 2007-08-29 曼康公司 Expression vectors encoding epitopes of target-associated antigens and its design method
DE102005041616B4 (en) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanoma associated MHC class I associated oligopeptides and polynucleotides encoding them and their uses
US8530182B2 (en) 2007-12-05 2013-09-10 Centers For Disease Control And Prevention Viral protein quantification process and vaccine quality control therewith

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2860875D1 (en) * 1977-09-28 1981-10-15 Nat Res Dev Immunological preparations incorporating mhc antigens and their production
DK1025849T5 (en) * 1992-12-22 2003-02-24 Ludwig Inst Cancer Res Methods for detecting and treating individuals having abnormal cells expressing HLC-A2 / tyrosinase peptide antigens
US6660276B1 (en) * 1994-02-16 2003-12-09 The University Of Virginia Patent Foundation Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
WO1998033810A2 (en) * 1997-01-30 1998-08-06 University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by a3-restricted cytotoxic lymphocytes, and uses therefor

Also Published As

Publication number Publication date
WO1997034613A1 (en) 1997-09-25
EP0921805A1 (en) 1999-06-16
AU712820B2 (en) 1999-11-18
EP0921805A4 (en) 2002-06-26
CA2249390C (en) 2007-12-18
AU2424397A (en) 1997-10-10

Similar Documents

Publication Publication Date Title
DE69529219D1 (en) Helicobacter proteine und impstoffe
IT1256333B (en) CLUTCH, IN PARTICULAR FOR VEHICLES, WITH HIGH FUNCTIONALITY AND DURABILITY
CA2189882A1 (en) Papillomavirus vaccines
EP1564824A3 (en) Energy conversion composition
AU6557190A (en) Vaccine composition with non-immunosuppressive t-cell epitope component
CA2267072A1 (en) Reconstituted human anti-hm1.24 antibody
EP0592202A3 (en) D-ketohexose 3-epimerase, and its preparation and uses.
CA2172507A1 (en) Methods and compositions for microencapsulation of antigens for use as vaccines
WO1995013297A3 (en) Improved immunogenic compositions against human gastrin 17
AU4556597A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
CA2249390A1 (en) Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
WO1995022561A3 (en) Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
AU662213B2 (en) Turbine and turbocharger using the same
AU1598500A (en) Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2
AUPO007396A0 (en) Ebv ctl epitopes
AU8876591A (en) Indole-3-methanamines useful as anti-diabetic, anti-obesity and anti-atherosclerotic agents
AU1086888A (en) Primary biliary cirrhosis autoantigen
WO1996002572A3 (en) Antigenic polypeptide sequence of factor viii, fragments and/or epitopes thereof
AU2913400A (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
AU6496094A (en) Tumor-associated antigens recognized by t cells and the uses of these antigens
IL98544A0 (en) Oxido reductase enzyme system obtainable from p.chrysogenum,its preparation and its use
AU2001273950A1 (en) Antibodies against native gp96, production and use thereof
AU636907B2 (en) Bovine ephemeral fever and antigens and vaccines derived therefrom
EP1096306A3 (en) Bichromal beads having charge adjuvants therein

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed